A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice

References

• Fauci AS, Morens DM. Zika virus in the Americas–Yet another Arbovirus threat. N Engl J Med. 2016;374(7):601–604. doi: 10.1056/NEJMp1600297
   PubMed Web of Science ®Google Scholar
• Vasconcelos PF, Monath TP. Yellow fever remains a potential threat to public health. Vector Borne Zoo Dis. 2016;16(8):566–567. doi: 10.1089/vbz.2016.2031
   PubMed Web of Science ®Google Scholar
• Barrett ADT. The reemergence of yellow fever. Science. 2018;361(6405):847–848. doi: 10.1126/science.aau8225
   PubMed Web of Science ®Google Scholar
• Shearer FM, Longbottom J, Browne AJ, et al. Existing and potential infection risk zones of yellow fever worldwide: a modelling analysis. Lancet Glob Health. 2018;6(3):e270–e2e8. doi: 10.1016/S2214-109X(18)30024-X
   PubMed Web of Science ®Google Scholar
• Theiler M, Smith HH. The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med. 1937;65(6):787–800. doi: 10.1084/jem.65.6.787
   PubMedGoogle Scholar
• Watson AM, Lam LK, Klimstra WB, et al. The 17D-204 vaccine strain-induced protection against virulent yellow fever virus is mediated by humoral immunity and CD4+ but not CD8+ T cells. PLoS Pathog. 2016;12(7):e1005786. doi: 10.1371/journal.ppat.1005786
   PubMed Web of Science ®Google Scholar
• Barrett AD, Teuwen DE. Yellow fever vaccine – how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol. 2009;21(3):308–313. doi: 10.1016/j.coi.2009.05.018
   PubMed Web of Science ®Google Scholar
• Reinhardt B, Jaspert R, Niedrig M, et al. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol. 1998;56(2):159–167. doi: 10.1002/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B
   PubMed Web of Science ®Google Scholar
• Poland JD, Calisher CH, Monath TP, et al. Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981;59(6):895–900.
   PubMed Web of Science ®Google Scholar
• Julander JG, Trent DW, Monath TP. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine. 2011;29(35):6008–6016. doi: 10.1016/j.vaccine.2011.06.034
   PubMed Web of Science ®Google Scholar
• Bassi MR, Kongsgaard M, Steffensen MA, et al. CD8+ t cells complement antibodies in protecting against yellow fever virus. J Immunol. 2015;194(3):1141–1153. doi: 10.4049/jimmunol.1402605
   PubMed Web of Science ®Google Scholar
• Sant AJ, McMichael A. Revealing the role of CD4(+) T cells in viral immunity. J Exp Med. 2012;209(8):1391–1395. doi: 10.1084/jem.20121517
   PubMed Web of Science ®Google Scholar
• Kum DB, Mishra N, Boudewijns R, et al. A yellow fever–Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice. Vaccines. 2018;3(1):56.
   Google Scholar
• ter Meulen J, Sakho M, Koulemou K, et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis. 2004;190(10):1821–1827. doi: 10.1086/425016
   PubMed Web of Science ®Google Scholar
• Malavige GN, Huang LC, Salimi M, et al. Cellular and cytokine correlates of severe dengue infection. PLoS One. 2012;7(11):e50387. doi: 10.1371/journal.pone.0050387
   PubMed Web of Science ®Google Scholar
• Lee YH, Leong WY, Wilder-Smith A. Markers of dengue severity: a systematic review of cytokines and chemokines. J Gen Virol. 2016;97(12):3103–3119. doi: 10.1099/jgv.0.000637
   PubMed Web of Science ®Google Scholar
• van der Most RG, Harrington LE, Giuggio V, et al. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology. 2002;296(1):117–124. doi: 10.1006/viro.2002.1432
   PubMed Web of Science ®Google Scholar
• de Melo AB, Nascimento EJ, Braga-Neto U, et al. T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and -II binding motifs. PLoS Negl Trop Dis. 2013;7(1):e1938. doi: 10.1371/journal.pntd.0001938
   PubMed Web of Science ®Google Scholar
• Akondy RS, Monson ND, Miller JD, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 2009;183(12):7919–7930. doi: 10.4049/jimmunol.0803903
   PubMed Web of Science ®Google Scholar
• James EA, LaFond RE, Gates TJ, et al. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins. J Virol. 2013;87(23):12794–12804. doi: 10.1128/JVI.01160-13
   PubMed Web of Science ®Google Scholar
• Abbink P, Larocca RA, De La Barrera RA, et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science. 2016;353(6304):1129–1132. doi: 10.1126/science.aah6157
   PubMed Web of Science ®Google Scholar
• Amorim JH, Diniz MO, Cariri FA, et al. Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant. Vaccine. 2012;30(5):837–845. doi: 10.1016/j.vaccine.2011.12.034
   PubMed Web of Science ®Google Scholar
• Schlesinger JJ, Brandriss MW, Cropp CB, et al. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J Virol. 1986;60(3):1153–1155. doi: 10.1128/JVI.60.3.1153-1155.1986
   PubMed Web of Science ®Google Scholar
• Akondy RS, Johnson PL, Nakaya HI, et al. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proc Natl Acad Sci U S A. 2015;112(10):3050–3055. doi: 10.1073/pnas.1500475112
   PubMed Web of Science ®Google Scholar
• Blom K, Braun M, Ivarsson MA, et al. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. J Immunol. 2013;190(5):2150–2158. doi: 10.4049/jimmunol.1202234
   PubMed Web of Science ®Google Scholar
• Lazear HM, Govero J, Smith AM, et al. A mouse model of Zika virus pathogenesis. Cell Host Microbe. 2016;19(5):720–730. doi: 10.1016/j.chom.2016.03.010
   PubMed Web of Science ®Google Scholar
• Zmurko J, Marques RE, Schols D, et al. The viral polymerase inhibitor 7-Deaza-2'-C-methyladenosine Is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl Trop Dis. 2016;10(5):e0004695. doi: 10.1371/journal.pntd.0004695
   PubMed Web of Science ®Google Scholar
• Kaptein SJ, De Burghgraeve T, Froeyen M, et al. A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro. Antimicrob Agents Chemother. 2010;54(12):5269–5280. doi: 10.1128/AAC.00686-10
   PubMed Web of Science ®Google Scholar
• Widman DG, Young E, Yount BL, et al. A reverse genetics platform that spans the Zika virus family tree. MBio. 2017;8(2):e02014–e02016. doi: 10.1128/mBio.02014-16
   Web of Science ®Google Scholar
• Thibodeaux BA, Garbino NC, Liss NM, et al. A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain. Vaccine. 2012;30(21):3180–3187. doi: 10.1016/j.vaccine.2012.03.003
   PubMed Web of Science ®Google Scholar
• World Health Organization. Correlates of vaccine-induced protection: methods and implications. WHO/IVB/13.01. 2013. https://www.who.int/immunization/documents/WHO_IVB_13.01/en/.
   Google Scholar
• Schlesinger JJ, Foltzer M, Chapman S. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology. 1993;192:132–141. doi: 10.1006/viro.1993.1015
   PubMed Web of Science ®Google Scholar
• Schlesinger JJ, Brandriss MW, Cropp CB, et al. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J Virol. 1986;60:1153–1155. doi: 10.1128/JVI.60.3.1153-1155.1986
   PubMed Web of Science ®Google Scholar
• Nasveld PE, Marjason J, Bennett S, et al. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity. Hum Vaccin. 2010;6:906–914. doi: 10.4161/hv.6.11.12854
   PubMed Web of Science ®Google Scholar
• Guy B, Nougarede N, Begue S, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine. 2008;26:5712–5721. doi: 10.1016/j.vaccine.2008.08.019
   PubMed Web of Science ®Google Scholar
• Harenberg A, Begue S, Mamessier A, et al. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum Vaccin Immunother. 2013;9:2317–2325. doi: 10.4161/hv.25562
   PubMed Web of Science ®Google Scholar